Low COVID-19 vaccine hesitancy in Brazil

Detalhes bibliográficos
Autor(a) principal: Moore, Daniella Campelo Batalha Cox
Data de Publicação: 2021
Outros Autores: Nehab, Marcio Fernandes, Camacho, Karla Gonçalves, Reis, Adriana Teixeira, Junqueira-Marinho, Maria de Fátima, Abramov, Dimitri Marques, Azevedo, Zina Maria Almeida de, Menezes, Livia Almeida de, Salú, Margarida dos Santos, Figueiredo, Carlos Eduardo da Silva, Moreira, Maria Elisabeth Lopes, Vasconcelos, Zilton Farias Meira de, Carvalho, Flavia Amendola Anisio de, Mello, Livia de Rezende de, Correia, Roberta Fernandes, Gomes Junior, Saint Clair dos Santos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/49928
Resumo: Declaration of Competing Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
id CRUZ_ee99eeb7c490aa7550b8e6385de454b3
oai_identifier_str oai:www.arca.fiocruz.br:icict/49928
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Moore, Daniella Campelo Batalha CoxNehab, Marcio FernandesCamacho, Karla GonçalvesReis, Adriana TeixeiraJunqueira-Marinho, Maria de FátimaAbramov, Dimitri MarquesAzevedo, Zina Maria Almeida deMenezes, Livia Almeida deSalú, Margarida dos SantosFigueiredo, Carlos Eduardo da SilvaMoreira, Maria Elisabeth LopesVasconcelos, Zilton Farias Meira deCarvalho, Flavia Amendola Anisio deMello, Livia de Rezende deCorreia, Roberta FernandesGomes Junior, Saint Clair dos Santos2021-11-22T19:40:02Z2021-11-22T19:40:02Z2021MOORE, Daniella Campelo Batalha Cox et al. Low COVID-19 vaccine hesitancy in Brazil. Vaccine, v. 39, n. 42, p. 6262-6268, 8 Oct. 2021.0264-410Xhttps://www.arca.fiocruz.br/handle/icict/4992810.1016/j.vaccine.2021.09.0130264-410XDeclaration of Competing Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.National Institute of Women, Children and Adolescents Health Fernandes Figueira, FIOCRUZ, Rio de Janeiro, Brazil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil / Universidade Federal Fluminense. Faculdade de Medicina. Niterói, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil / Universidade do Estado do Rio de Janeiro. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil / Universidade do Grande Rio. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Background: The COVID-19 pandemic has affected the entire world, and the vaccine has emerged as a source of hope for return to normal life. Still, various countries have reported high vaccine hesitancy rates. It is important to know the vaccine hesitancy profile in Brazil to help design adequate communication strategies. Methods: A voluntary, anonymous online survey was conducted from January 22 to 29, 2021, including resident Brazilian adults to assess factors related to vaccine hesitancy. Sociodemographic and epidemiological data were analyzed. A bivariate analysis was conducted with the independent variables, with vaccine hesitancy as the outcome variable, and a multivariate logistic model was used to calculated adjusted odds ratios. Results: The sample included 173,178 respondents, and vaccine hesitancy was found in 10.5%. The principal factors associated with vaccine hesitancy were the following: assigning importance to the vaccinés efficacy (AOR = 16.39), fear of adverse reactions (AOR = 11.23), and assigning importance to the vaccinés country of origin (AOR = 3.72). Other risk factors were the following: male gender (AOR = 1.62), having children (AOR = 1.29), 9 years of schooling or less (AOR = 1.31), living in the Central-West region (AOR = 1.19), age ≥ 40 years (AOR = 1.17), and monthly income < U$788.68 (AOR = 1.13). The two vaccines available in Brazil, Covishield and CoronaVac, showed similar confidence, 80.13% and 76.36%, respectively, despite the higher rejection of the latter vaccinés Chinese origin. Interpretation: This online survey confirms the low vaccine hesitancy rate among Brazilians and allowed the identification of a profile that can assist the elaboration of communication strategies to increase vaccine adherence.engElsevierAdolescentAdultBrazilVaccinesCOVID-19HumansMalePandemicsVaccine hesitancyBrazilSurveyAdverse reactionsVaccineEfficacySARS-CoV-2COVID-19Low COVID-19 vaccine hesitancy in Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83132https://www.arca.fiocruz.br/bitstream/icict/49928/1/license.txt33967fcc8ef681b8f5c2c34178ebc114MD51ORIGINALve_Daniella_Moore_etal_IFF_2021.pdfve_Daniella_Moore_etal_IFF_2021.pdfapplication/pdf555655https://www.arca.fiocruz.br/bitstream/icict/49928/2/ve_Daniella_Moore_etal_IFF_2021.pdfbf9d07478a52a15babb8ee9756fc2bf9MD52icict/499282023-02-15 22:52:21.272oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-02-16T01:52:21Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en.fl_str_mv Low COVID-19 vaccine hesitancy in Brazil
title Low COVID-19 vaccine hesitancy in Brazil
spellingShingle Low COVID-19 vaccine hesitancy in Brazil
Moore, Daniella Campelo Batalha Cox
Adolescent
Adult
Brazil
Vaccines
COVID-19
Humans
Male
Pandemics
Vaccine hesitancy
Brazil
Survey
Adverse reactions
Vaccine
Efficacy
SARS-CoV-2
COVID-19
title_short Low COVID-19 vaccine hesitancy in Brazil
title_full Low COVID-19 vaccine hesitancy in Brazil
title_fullStr Low COVID-19 vaccine hesitancy in Brazil
title_full_unstemmed Low COVID-19 vaccine hesitancy in Brazil
title_sort Low COVID-19 vaccine hesitancy in Brazil
author Moore, Daniella Campelo Batalha Cox
author_facet Moore, Daniella Campelo Batalha Cox
Nehab, Marcio Fernandes
Camacho, Karla Gonçalves
Reis, Adriana Teixeira
Junqueira-Marinho, Maria de Fátima
Abramov, Dimitri Marques
Azevedo, Zina Maria Almeida de
Menezes, Livia Almeida de
Salú, Margarida dos Santos
Figueiredo, Carlos Eduardo da Silva
Moreira, Maria Elisabeth Lopes
Vasconcelos, Zilton Farias Meira de
Carvalho, Flavia Amendola Anisio de
Mello, Livia de Rezende de
Correia, Roberta Fernandes
Gomes Junior, Saint Clair dos Santos
author_role author
author2 Nehab, Marcio Fernandes
Camacho, Karla Gonçalves
Reis, Adriana Teixeira
Junqueira-Marinho, Maria de Fátima
Abramov, Dimitri Marques
Azevedo, Zina Maria Almeida de
Menezes, Livia Almeida de
Salú, Margarida dos Santos
Figueiredo, Carlos Eduardo da Silva
Moreira, Maria Elisabeth Lopes
Vasconcelos, Zilton Farias Meira de
Carvalho, Flavia Amendola Anisio de
Mello, Livia de Rezende de
Correia, Roberta Fernandes
Gomes Junior, Saint Clair dos Santos
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Moore, Daniella Campelo Batalha Cox
Nehab, Marcio Fernandes
Camacho, Karla Gonçalves
Reis, Adriana Teixeira
Junqueira-Marinho, Maria de Fátima
Abramov, Dimitri Marques
Azevedo, Zina Maria Almeida de
Menezes, Livia Almeida de
Salú, Margarida dos Santos
Figueiredo, Carlos Eduardo da Silva
Moreira, Maria Elisabeth Lopes
Vasconcelos, Zilton Farias Meira de
Carvalho, Flavia Amendola Anisio de
Mello, Livia de Rezende de
Correia, Roberta Fernandes
Gomes Junior, Saint Clair dos Santos
dc.subject.mesh.pt_BR.fl_str_mv Adolescent
Adult
Brazil
Vaccines
COVID-19
Humans
Male
Pandemics
topic Adolescent
Adult
Brazil
Vaccines
COVID-19
Humans
Male
Pandemics
Vaccine hesitancy
Brazil
Survey
Adverse reactions
Vaccine
Efficacy
SARS-CoV-2
COVID-19
dc.subject.en.en.fl_str_mv Vaccine hesitancy
Brazil
Survey
Adverse reactions
Vaccine
Efficacy
SARS-CoV-2
COVID-19
description Declaration of Competing Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
publishDate 2021
dc.date.accessioned.fl_str_mv 2021-11-22T19:40:02Z
dc.date.available.fl_str_mv 2021-11-22T19:40:02Z
dc.date.issued.fl_str_mv 2021
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv MOORE, Daniella Campelo Batalha Cox et al. Low COVID-19 vaccine hesitancy in Brazil. Vaccine, v. 39, n. 42, p. 6262-6268, 8 Oct. 2021.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/49928
dc.identifier.issn.pt_BR.fl_str_mv 0264-410X
dc.identifier.doi.pt_BR.fl_str_mv 10.1016/j.vaccine.2021.09.013
dc.identifier.eissn.pt_BR.fl_str_mv 0264-410X
identifier_str_mv MOORE, Daniella Campelo Batalha Cox et al. Low COVID-19 vaccine hesitancy in Brazil. Vaccine, v. 39, n. 42, p. 6262-6268, 8 Oct. 2021.
0264-410X
10.1016/j.vaccine.2021.09.013
url https://www.arca.fiocruz.br/handle/icict/49928
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/49928/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/49928/2/ve_Daniella_Moore_etal_IFF_2021.pdf
bitstream.checksum.fl_str_mv 33967fcc8ef681b8f5c2c34178ebc114
bf9d07478a52a15babb8ee9756fc2bf9
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008904738570240